Annual FCF
-$32.99 M
-$25.26 M-326.79%
December 31, 2023
Summary
- As of February 8, 2025, SPRO annual free cash flow is -$32.99 million, with the most recent change of -$25.26 million (-326.79%) on December 31, 2023.
- During the last 3 years, SPRO annual FCF has risen by +$53.03 million (+61.65%).
- SPRO annual FCF is now -326.79% below its all-time high of -$7.73 million, reached on December 31, 2022.
Performance
SPRO Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly FCF
$12.76 M
+$31.51 M+168.09%
September 30, 2024
Summary
- As of February 8, 2025, SPRO quarterly free cash flow is $12.76 million, with the most recent change of +$31.51 million (+168.09%) on September 30, 2024.
- Over the past year, SPRO quarterly FCF has increased by +$30.26 million (+172.96%).
- SPRO quarterly FCF is now -71.31% below its all-time high of $44.48 million, reached on December 31, 2022.
Performance
SPRO Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM FCF
-$17.54 M
-$3.15 M-21.91%
September 30, 2024
Summary
- As of February 8, 2025, SPRO TTM free cash flow is -$17.54 million, with the most recent change of -$3.15 million (-21.91%) on September 30, 2024.
- Over the past year, SPRO TTM FCF has increased by +$15.46 million (+46.85%).
- SPRO TTM FCF is now -160.51% below its all-time high of $28.98 million, reached on September 30, 2023.
Performance
SPRO TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Free Cash Flow Formula
FCF = Cash From Operations − CAPEX
SPRO Free Cash Flow Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -326.8% | +173.0% | +46.9% |
| 3 y3 years | +61.6% | +173.0% | +46.9% |
| 5 y5 years | +21.6% | +173.0% | +46.9% |
SPRO Free Cash Flow Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -326.8% | +48.7% | -71.3% | +145.2% | -160.5% | +79.0% |
| 5 y | 5-year | -326.8% | +61.6% | -71.3% | +145.2% | -160.5% | +79.9% |
| alltime | all time | -326.8% | +61.6% | -71.3% | +145.2% | -160.5% | +79.9% |
Spero Therapeutics Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $12.76 M(-168.1%) | -$17.54 M(+21.9%) |
| Jun 2024 | - | -$18.74 M(-415.7%) | -$14.38 M(+1.3%) |
| Mar 2024 | - | $5.94 M(-133.9%) | -$14.20 M(-57.0%) |
| Dec 2023 | -$32.99 M(+326.8%) | -$17.49 M(-209.9%) | -$32.99 M(-213.9%) |
| Sep 2023 | - | $15.91 M(-185.7%) | $28.98 M(+139.3%) |
| Jun 2023 | - | -$18.56 M(+44.4%) | $12.11 M(+58.5%) |
| Mar 2023 | - | -$12.85 M(-128.9%) | $7.64 M(-198.8%) |
| Dec 2022 | -$7.73 M(-88.0%) | $44.48 M(-4748.1%) | -$7.73 M(-90.3%) |
| Sep 2022 | - | -$957.00 K(-95.8%) | -$79.56 M(-4.8%) |
| Jun 2022 | - | -$23.03 M(-18.4%) | -$83.56 M(+8.4%) |
| Mar 2022 | - | -$28.22 M(+3.2%) | -$77.09 M(+19.8%) |
| Dec 2021 | -$64.35 M(-25.2%) | -$27.35 M(+452.3%) | -$64.35 M(+20.5%) |
| Sep 2021 | - | -$4.95 M(-70.1%) | -$53.39 M(-23.5%) |
| Jun 2021 | - | -$16.57 M(+7.0%) | -$69.76 M(-10.7%) |
| Mar 2021 | - | -$15.48 M(-5.6%) | -$78.10 M(-9.2%) |
| Dec 2020 | -$86.03 M | -$16.39 M(-23.1%) | -$86.03 M(-1.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2020 | - | -$21.32 M(-14.4%) | -$87.13 M(+15.4%) |
| Jun 2020 | - | -$24.91 M(+6.4%) | -$75.49 M(+20.3%) |
| Mar 2020 | - | -$23.41 M(+33.8%) | -$62.74 M(+24.6%) |
| Dec 2019 | -$50.33 M(+19.7%) | -$17.50 M(+80.8%) | -$50.33 M(+3.2%) |
| Sep 2019 | - | -$9.68 M(-20.4%) | -$48.76 M(+9.3%) |
| Jun 2019 | - | -$12.16 M(+10.5%) | -$44.62 M(+8.6%) |
| Mar 2019 | - | -$11.01 M(-30.9%) | -$41.10 M(-2.3%) |
| Dec 2018 | -$42.06 M(+7.5%) | -$15.92 M(+187.6%) | -$42.06 M(+8.2%) |
| Sep 2018 | - | -$5.54 M(-35.9%) | -$38.88 M(-11.4%) |
| Jun 2018 | - | -$8.64 M(-27.8%) | -$43.86 M(-0.5%) |
| Mar 2018 | - | -$11.96 M(-6.1%) | -$44.09 M(+12.7%) |
| Dec 2017 | -$39.14 M(+31.4%) | -$12.74 M(+21.2%) | -$39.11 M(+48.3%) |
| Sep 2017 | - | -$10.52 M(+18.5%) | -$26.37 M(+66.3%) |
| Jun 2017 | - | -$8.88 M(+27.2%) | -$15.86 M(+127.2%) |
| Mar 2017 | - | -$6.98 M | -$6.98 M |
| Dec 2016 | -$29.79 M(+202.7%) | - | - |
| Dec 2015 | -$9.84 M | - | - |
FAQ
- What is Spero Therapeutics annual free cash flow?
- What is the all time high annual FCF for Spero Therapeutics?
- What is Spero Therapeutics annual FCF year-on-year change?
- What is Spero Therapeutics quarterly free cash flow?
- What is the all time high quarterly FCF for Spero Therapeutics?
- What is Spero Therapeutics quarterly FCF year-on-year change?
- What is Spero Therapeutics TTM free cash flow?
- What is the all time high TTM FCF for Spero Therapeutics?
- What is Spero Therapeutics TTM FCF year-on-year change?
What is Spero Therapeutics annual free cash flow?
The current annual FCF of SPRO is -$32.99 M
What is the all time high annual FCF for Spero Therapeutics?
Spero Therapeutics all-time high annual free cash flow is -$7.73 M
What is Spero Therapeutics annual FCF year-on-year change?
Over the past year, SPRO annual free cash flow has changed by -$25.26 M (-326.79%)
What is Spero Therapeutics quarterly free cash flow?
The current quarterly FCF of SPRO is $12.76 M
What is the all time high quarterly FCF for Spero Therapeutics?
Spero Therapeutics all-time high quarterly free cash flow is $44.48 M
What is Spero Therapeutics quarterly FCF year-on-year change?
Over the past year, SPRO quarterly free cash flow has changed by +$30.26 M (+172.96%)
What is Spero Therapeutics TTM free cash flow?
The current TTM FCF of SPRO is -$17.54 M
What is the all time high TTM FCF for Spero Therapeutics?
Spero Therapeutics all-time high TTM free cash flow is $28.98 M
What is Spero Therapeutics TTM FCF year-on-year change?
Over the past year, SPRO TTM free cash flow has changed by +$15.46 M (+46.85%)